Lineage, Inc. Common Stock (LINE)vsSL Green Realty Corp (SLG)
LINE
Lineage, Inc. Common Stock
$42.63
-1.32%
REAL ESTATE · Cap: $11.14B
SLG
SL Green Realty Corp
$47.83
+1.51%
REAL ESTATE · Cap: $3.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 472% more annual revenue ($5.36B vs $937.37M). LINE leads profitability with a -2.7% profit margin vs -16.2%. SLG earns a higher WallStSmart Score of 37/100 (F).
LINE
Avoid34
out of 100
Grade: F
SLG
Hold37
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Reasonable price relative to book value
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
Elevated debt levels
Operating margin of 1.3%
Elevated debt levels
Weak financial health signals
ROE of -3.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : SLG
The strongest argument for SLG centers on Price/Book. PEG of 1.30 suggests the stock is reasonably priced for its growth.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : SLG
The primary concerns for SLG are Operating Margin, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.75 is elevated, increasing financial risk.
Key Dynamics to Monitor
LINE is growing revenue faster at 0.4% — sustainability is the question.
SLG generates stronger free cash flow (56M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SLG scores higher overall (37/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is an innovative biotechnology company specializing in regenerative medicine, with a focus on developing state-of-the-art cell therapies for conditions such as ocular diseases, spinal cord injuries, and various cancers. Leveraging its proprietary technologies and strong strategic partnerships, Lineage aims to revolutionize patient care with pioneering therapeutic solutions. The company’s dedication to advancing its diverse product pipeline and accelerating clinical trials positions it as a compelling investment prospect for institutional investors looking to engage at the cutting edge of healthcare advancements.
Visit Website →Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?